OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases
Jeffrey R. Curtis, Alexis Ogdie, Michael George
JAMA (2021) Vol. 325, Iss. 17, pp. 1726-1726
Closed Access | Times Cited: 9
Jeffrey R. Curtis, Alexis Ogdie, Michael George
JAMA (2021) Vol. 325, Iss. 17, pp. 1726-1726
Closed Access | Times Cited: 9
Showing 9 citing articles:
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, et al.
JAMA (2021) Vol. 326, Iss. 23, pp. 2375-2375
Open Access | Times Cited: 116
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, et al.
JAMA (2021) Vol. 326, Iss. 23, pp. 2375-2375
Open Access | Times Cited: 116
Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
Marthe Kirkesæther Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, et al.
Journal of Internal Medicine (2022) Vol. 292, Iss. 3, pp. 477-491
Open Access | Times Cited: 25
Marthe Kirkesæther Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, et al.
Journal of Internal Medicine (2022) Vol. 292, Iss. 3, pp. 477-491
Open Access | Times Cited: 25
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, et al.
BioDrugs (2022) Vol. 36, Iss. 6, pp. 731-748
Open Access | Times Cited: 23
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, et al.
BioDrugs (2022) Vol. 36, Iss. 6, pp. 731-748
Open Access | Times Cited: 23
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control
Siri Lillegraven, Nina Paulshus Sundlisæter, Anna‐Birgitte Aga, et al.
JAMA (2023) Vol. 329, Iss. 12, pp. 1024-1024
Open Access | Times Cited: 4
Siri Lillegraven, Nina Paulshus Sundlisæter, Anna‐Birgitte Aga, et al.
JAMA (2023) Vol. 329, Iss. 12, pp. 1024-1024
Open Access | Times Cited: 4
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases—Reply
Silje Watterdal Syversen, Nils Bolstad, Espen A. Haavardsholm
JAMA (2021) Vol. 326, Iss. 11, pp. 1069-1069
Closed Access | Times Cited: 7
Silje Watterdal Syversen, Nils Bolstad, Espen A. Haavardsholm
JAMA (2021) Vol. 326, Iss. 11, pp. 1069-1069
Closed Access | Times Cited: 7
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases
Olivier Le Tilly, Gilles Paintaud, David Ternant
JAMA (2021) Vol. 326, Iss. 11, pp. 1069-1069
Closed Access | Times Cited: 1
Olivier Le Tilly, Gilles Paintaud, David Ternant
JAMA (2021) Vol. 326, Iss. 11, pp. 1069-1069
Closed Access | Times Cited: 1
Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis
Kenneth F. Baker, Arthur G. Pratt, John D. Isaacs
JAMA (2021) Vol. 326, Iss. 9, pp. 872-872
Closed Access
Kenneth F. Baker, Arthur G. Pratt, John D. Isaacs
JAMA (2021) Vol. 326, Iss. 9, pp. 872-872
Closed Access
Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis—Reply
Siri Lillegraven, Nina Paulshus Sundlisæter, Espen A. Haavardsholm
JAMA (2021) Vol. 326, Iss. 9, pp. 873-873
Closed Access
Siri Lillegraven, Nina Paulshus Sundlisæter, Espen A. Haavardsholm
JAMA (2021) Vol. 326, Iss. 9, pp. 873-873
Closed Access
